相似文献
1
The role of genetic diversity in cancer.
J Clin Invest. 2010 Feb;120(2):401-3. doi: 10.1172/JCI42088. Epub 2010 Jan 25.
2
[Establishing a cytogenetic and morphological progression models of invasive breast cancer. Comparative genomic hybridization (CGH) in malignant and premalignant tumors of the female breast].
Pathologe. 2000 Sep;21(5):375-82. doi: 10.1007/s002920000404.
3
Increasing chromosome 1 copy number parallels histological progression in breast carcinogenesis.
Br J Cancer. 2000 Mar;82(6):1204-10. doi: 10.1054/bjoc.1999.1064.
4
Genomics and premalignant breast lesions: clues to the development and progression of lobular breast cancer.
Breast Cancer Res. 2007;9(6):215. doi: 10.1186/bcr1785.
5
Cell biology of precancer.
Eur J Cancer. 2001 Oct;37 Suppl 8:S97-113. doi: 10.1016/s0959-8049(01)00277-5.
6
Lobular neoplasia.
Surg Oncol Clin N Am. 2014 Jul;23(3):487-503. doi: 10.1016/j.soc.2014.03.002. Epub 2014 Apr 16.
7
Genetic and molecular markers of urothelial premalignancy and malignancy.
Scand J Urol Nephrol Suppl. 2000(205):82-93. doi: 10.1080/003655900750169338.
8
Diversity counts. Visualizing pretumor progression in the gastrointestinal tract.
Am J Clin Pathol. 2011 Jun;135(6):878-88. doi: 10.1309/AJCPP3I5HDYWMHJA.
9
Familial risks in in situ cancers from the Family-Cancer Database.
Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):865-8.
10
Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Mod Pathol. 2002 Feb;15(2):116-24. doi: 10.1038/modpathol.3880503.
引用本文的文献
1
Forward-reverse mutation cycles in cancer cell lines under chemical treatments.
Hum Genomics. 2024 Sep 27;18(1):106. doi: 10.1186/s40246-024-00661-1.
2
The Clinical Significance of Genetic Variation in Ovarian Cancer.
Int J Mol Sci. 2023 Jun 28;24(13):10823. doi: 10.3390/ijms241310823.
3
Why is cancer becoming a global endemic today?
Int J Health Sci (Qassim). 2020 Sep-Oct;14(5):1-2.
4
Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models.
Comput Struct Biotechnol J. 2020 Jan 31;18:323-331. doi: 10.1016/j.csbj.2020.01.008. eCollection 2020.
5
Rethinking Causation in Cancer with Evolutionary Developmental Biology.
Biol Theory. 2018;13(4):228-242. doi: 10.1007/s13752-018-0303-0. Epub 2018 Jul 27.
6
Domesticating Cancer: An Evolutionary Strategy in the War on Cancer.
Front Oncol. 2017 Dec 7;7:304. doi: 10.3389/fonc.2017.00304. eCollection 2017.
7
Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells.
Prostate. 2018 Feb;78(3):233-238. doi: 10.1002/pros.23462. Epub 2017 Nov 22.
8
Natural Selection in Cancer Biology: From Molecular Snowflakes to Trait Hallmarks.
Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):a029652. doi: 10.1101/cshperspect.a029652.
9
Evolutionary scalpels for dissecting tumor ecosystems.
Biochim Biophys Acta Rev Cancer. 2017 Apr;1867(2):69-83. doi: 10.1016/j.bbcan.2016.11.005. Epub 2016 Dec 5.
10
Cancer Bioinformatic Methods to Infer Meaningful Data From Small-Size Cohorts.
Cancer Inform. 2015 Nov 2;14:131-9. doi: 10.4137/CIN.S32696. eCollection 2015.
本文引用的文献
1
Cancer research meets evolutionary biology.
Evol Appl. 2009 Feb;2(1):62-70. doi: 10.1111/j.1752-4571.2008.00063.x.
2
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype.
J Clin Invest. 2010 Feb;120(2):636-44. doi: 10.1172/JCI40724. Epub 2010 Jan 25.
3
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.
Nat Rev Cancer. 2009 Apr;9(4):265-73. doi: 10.1038/nrc2620. Epub 2009 Mar 5.
4
Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers.
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4828-33. doi: 10.1073/pnas.0810276106. Epub 2009 Mar 4.
5
Efficient tumour formation by single human melanoma cells.
Nature. 2008 Dec 4;456(7222):593-8. doi: 10.1038/nature07567.
6
Microenvironmental regulation of cancer development.
Curr Opin Genet Dev. 2008 Feb;18(1):27-34. doi: 10.1016/j.gde.2007.12.006. Epub 2008 Feb 20.
7
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
J Clin Invest. 2007 Sep;117(9):2562-9. doi: 10.1172/JCI30890.
8
Molecular definition of breast tumor heterogeneity.
Cancer Cell. 2007 Mar;11(3):259-73. doi: 10.1016/j.ccr.2007.01.013.
9
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
PLoS Med. 2007 Feb;4(2):e67. doi: 10.1371/journal.pmed.0040067.
10
Stochastic cancer progression driven by non-clonal chromosome aberrations.
J Cell Physiol. 2006 Aug;208(2):461-72. doi: 10.1002/jcp.20685.
Zotero 插件